Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to Lamivudine

Entecavir (ETV) exhibits potent antiviral activity in patients chronically infected with wild-type or lamivudine (3TC)-resistant (3TC(r)) hepatitis B virus (HBV). Among the patients treated in phase II ETV clinical trials, two patients for whom previous therapies had failed exhibited virologic break...

全面介紹

Na minha lista:
書目詳細資料
發表在:Antimicrob Agents Chemother
Main Authors: Tenney, D. J., Levine, S. M., Rose, R. E., Walsh, A. W., Weinheimer, S. P., Discotto, L., Plym, M., Pokornowski, K., Yu, C. F., Angus, P., Ayres, A., Bartholomeusz, A., Sievert, W., Thompson, G., Warner, N., Locarnini, S., Colonno, R. J.
格式: Artigo
語言:Inglês
出版: American Society for Microbiology (ASM) 2004
主題:
Antiviral Agents
在線閱讀:https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC514758/
https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/15328117/
https://ncbi.nlm.nih.govhttps://doi.org/10.1128/AAC.48.9.3498-3507.2004
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍